Recently, researchers have found that in patients with r/r B-ALL who received CD19 CAR-T therapy, TP53 mutation (TP53-mut) in somatic cells was significantly associated with a poor prognosis after CAR-T therapy (11). The gene discussed is TP53; the disease is acute lymphoblastic leukemia.